Provision of WES Trio and Singleton Virtual Panel Analysis for Welsh Patients

Procurement agent: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)·On behalf of: Swansea University

ServicesAward procedure without prior publication of a call for competition

Sectors: Architecture & Engineering (71) Delivery: Wales (UKL22)

Awarded value£275,000published contract · exc. VAT

Awarded 11 Jun 2021no call for competition

Awarded to CeGat GmbH

What is being bought

Published requirement description

In-line with All Wales Medical Genomic Service’s (AWMGS) commissioning model, AWMGS will procure from CeGaT whole exom sequencing (WES) for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. This genetic testing will ensure equity of access to genomic testing for Welsh patients and meet their need to seek a timely genetic diagnosis for their rare or inherited disease.

CPV: Laboratory services

The lotProcurement structure

single lot · no lot value published

Lot #1NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale…

NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGS, for the supply of WES single and trio based testing from CeGAT. The contract is estimated to commence in July 2021, for a period of two years. The first year’s delivery will be capped at 175,000 GBP and reviewed to ensure that value for money is being achieved through the pick-up rate of pathogenic findings as a means of ensuring appropriate referrals and use of this bespoke service. The second year’s service will be capped at estimated 100,000 GBP assuming AWMGS are able to deliver in-house WES-based testing for Welsh patients within 2022/23 as currently planned.

Delivery: Wales · All Wales Medical Genomics Service, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW

Procedure terms & legal framework

From the official record · publisher note attached

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Services
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 24 Jun 2021, 15:04 BST
Last source update: 24 Jun 2021, 15:04 BST
Authority reference: CAV-STA (2021/2022) 11
FTS notice number: 2021/S 000-014421
Classification (CPV): Laboratory services
Delivery area: Wales (UKL22)
Official registry OCID: ocds-h6vhtk-02bfc8 Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: All Wales Genomics Service (AWMGS) is commissioned by the Wealth Health Specialist Services Commission (WHSSC) to provide genetic testing for Welsh patients which is equitable to the provision NHS E makes available through the Rare and Inherited Disease Test Directory. NHS E patients can currently access a range of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) tests for rare and inheritable diseases which the laboratory is unable to deliver in-house. In-house service developments are ongoing to enable the delivery of equivalent genetic tests but these will not go-live until 2022 – 24 (services will be introduced over a 18-24 month basis).
Where feasible, AWMGS commission genetic tests from within the NHS network for Welsh patients. NHS E genetic laboratories currently provide Welsh patients with access to a small number of trio WES-based tests, e.g. Exeter genetic laboratory provides and a larger number of phenotype driven singleton virtual panel tests. Importantly, WGS based testing is not available at all to AWMGS patients from NHS E laboratories due to the centralised model developed by Genetics England.
AWMGS will procure from CeGaT WES for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. For Single Exome Diagnostics, CeGaT will analyse a virtual panel of genes that are known to be associated with the patient’s phenotype. The virtual panel will be selected from a list of panels that have been curated by the NHS Genomic Medicine Service and are aligned to the NHSE Test Directory. These panels can be found at panelapp.genomicsengland.co.uk ↗
Targeted analysis of the ACMG genes is NOT requested for any samples received from AWMGS.
Should incidental or secondary findings be identified through routine analysis and not as part of a targeted analysis, these may reported to the referring clinician depending on the preference of the patient that will be indicated on the customised referral form that has been designed to meet the needs of the AWMGS service.
There is no alternative supplier within Europe providing an equivalent customised WES trio or singleton service to CeGAT which delivers against PanelApp green gene lists. Through procuring this specialist service from CeGAT AWMGS will ensure equity of access to genetic testing across NHS E and NHS W patient cohort in line with the commissioning model agreed with WHSSC.

Review and risk notes

Review procedure: The Authority will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract. Should additional information be required from the addressee in section 1.1 Ryan James ([email protected]).
The Contracting Authority will enter into this Contract following a minimum 10 day calendar day standstill period starting on the day after this notice is published onFind a Tender. If legal proceedings are commenced in relation to the contract award, it will be necessary to suspend the award of the contract pending further order of the Court, or the authority may voluntarily decide (at its discretion) to suspend the award of contract whilst any outstanding queries are dealt with. We will not be liable for any costs or losses incurred by you as a result of any suspension of the contract award or as a result of any other action made necessary by any challenge.

Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111599. (WA Ref:111599)

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £275,0001 contract exc. VAT

Contracts signed 1latest 11 Jun 2021

Awarded to	Value	Date	Status
CeGat GmbH	£275,000 †	—	Awarded

Contracts

Contract 014421-2021-CAV-STA (2021/2022) 11-1 · CeGat GmbH
Signed
11 Jun 2021
Value
£275,000
Status
active

Contracting authority & participating public bodies

2 public bodies on the notice

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Procurement agentBody governed by public lawHealth 2nd Floor Woodland House, Cardiff, UK, CF14 4TTContact name, email, phone

Clients of the procurement agent

Swansea UniversityBeneficiary authority

Dispute resolution & review bodies

High CourtReview body LondonContact phone

Bidders & participating suppliers

1 commercial party on the notice

CeGaT GmbHAwarded supplier Paul-Ehrlich-Straße 23, Tubingen, DE1, D72076Contact phone

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.